baicalin has been researched along with Hyperlipemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, YQ; Jiang, ZM; Liu, EH; Liu, WJ; Wang, ZY; Xiao, PT | 1 |
| Cheng, M; Deng, G; Ju, M; Kang, X; Li, M; Liu, H; Liu, Y; Zhang, Y | 1 |
2 other study(ies) available for baicalin and Hyperlipemia
| Article | Year |
|---|---|
The mechanisms of baicalin ameliorate obesity and hyperlipidemia through a network pharmacology approach.
Topics: Amino Acid Sequence; Anti-Obesity Agents; Caspase 3; Drug Discovery; Flavonoids; Gene Expression Regulation; Glucose Transporter Type 1; Hep G2 Cells; Herbal Medicine; Humans; Hyperlipidemias; Hypolipidemic Agents; Models, Molecular; Molecular Structure; NF-kappa B p50 Subunit; Obesity; Plant Extracts; Protein Binding; Protein Conformation; Scutellaria baicalensis; Signal Transduction; Sterol Regulatory Element Binding Protein 1; Structure-Activity Relationship; Tumor Necrosis Factor-alpha | 2020 |
Baicalin improves intestinal microecology and abnormal metabolism induced by high-fat diet.
Topics: Animals; Body Weight; Diet, High-Fat; Eating; Fatty Acids, Volatile; Feces; Flavonoids; Gastrointestinal Microbiome; Glucaric Acid; Glucose; Hyperlipidemias; Intestinal Mucosa; Male; Mice; Mice, Inbred C57BL; Obesity | 2019 |